NMT-A02 shows higher efficacy and lower toxicity against all 3 animal models tested (mice, hamster and dog). Excellent results were obtained in dogs clinical trial in comparison with Milteforan® (the standard oral treatment): rapid clinical recovery, reduction of parasite burden, absence of significant key biopathological markers and reduction of IFAT titers as a diagnostic method.
NMT-A02 performs better than Milteforan®, which prompted us to propose the dogs’ adoption as a follow-up of the trial. A permit was granted by the Comunidad de Madrid Government on 11-11-2016. The agreement between the adopters and UCM was to continue the follow-up of the dogs: UCM had access to the dogs (immunology, biopathology, hematology) through their veterinarians. Follow-up results are: the NMT-A02 group of dogs showed better recovery, is in good clinical conditions and no other treatment was received after the end of the trial in contrast to the Milteforan® treated group .
Addressing target audiences and expressing needs
- Business partners – SMEs, Entrepreneurs, Large Corporations
We need to complete the late preclinical studies. Two options are available, depending on the stakeholder interest:
a. for use against canine Leishmaniasis a trial in natural infected dogs, a pharmaceutical formulation, final IND for marketing.
b. for human Leishmaniasis use. Completing the GLP preclinical trials, select NMT-A02 formulation. File IND (regulatory) for phase 1 trial. Phase 1 performance.
- Other Actors who can help us fulfil our market potential
R&D, Technology and Innovation aspects
A drug lead with efficacy and safety in the natural reservoir of leishmaniasis (dogs). Potential use for humans.
Efficacy and toxicology on 3 animal models (mice, hamsters and dogs), follow-up after two years on dogs of the trial.
Funding is needed to progress to late preclinical studies, pharmaceutical formulation and regulatory for marketing.
Transfer of knowledge available, IP available.
